No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30 days course of nitazoxanide monotherapy

被引：4
|
作者：
Laufer, N. [1 ,2 ,3 ]
Abusamra, L. [2 ,4 ]
Bolcic, F. [3 ]
Gun, A. [4 ]
Rolon, M. J. [2 ]
Perez, H. [2 ]
Krolewiecki, A. [4 ]
Salomon, H. [3 ]
Quarleri, J. [3 ]
Cahn, P. [2 ,4 ]
机构：
[1] Univ Buenos Aires, Fac Med, CONICET, Ctr Nacl Referencia SIDA,Dept Microbiol, Buenos Aires, DF, Argentina
[2] Hosp Fernandez, Div Enfermedades Infecciosas, Buenos Aires, DF, Argentina
[3] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina
[4] Fdn Huesped, Buenos Aires, DF, Argentina
来源：
ANTIVIRAL RESEARCH | 2011年 / 92卷 / 03期
关键词：
Nitazoxanide; HCV genotype 1; HIV/HCV co-infection; HCV treatment; CHRONIC HEPATITIS-C; RANDOMIZED CONTROLLED-TRIAL; ZAMBIAN CHILDREN; VIRUS; CRYPTOSPORIDIOSIS; PEGINTERFERON; TIZOXANIDE; INHIBITORS; RIBAVIRIN; THERAPY;
D O I：
10.1016/j.antiviral.2011.10.006
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
There are two new drugs approved and several in development for treatment of chronic HCV; among them nitazoxanide (NTZ). Twelve HIV/HCV genotype 1 co-infected patients were enrolled prospectively to receive a 30 days course of oral NTZ 500 mg bid. This therapy was well tolerated in this group of HIV patients co-infected with HCV genotype 1. Nevertheless no changes in HCV viral load were observed during treatment in none of the patients evaluated. This data suggests that despite the promising results reported for HCV genotype 4 mono-infected patients, NTZ exhibit poor activity as monotherapy in HIV/HCV co-infected patients with genotype 1. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码：497 / 499
页数：3
相关论文
共 50 条
  • [1] Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
    Marzieh Jamalidoust
    Mandana Namayandeh
    Mohsen Moghadami
    Mazyar Ziyaeyan
    Virology Journal, 14
  • [2] Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
    Jamalidoust, Marzieh
    Namayandeh, Mandana
    Moghadami, Mohsen
    Ziyaeyan, Mazyar
    VIROLOGY JOURNAL, 2017, 14
  • [3] MicroRNAs Profiling in HIV, HCV, and HIV/HCV Co-Infected Patients
    Moghoofei, Mohsen
    Najafipour, Sohrab
    Mostafaei, Shayan
    Tavakoli, Ahmad
    Bokharaei-Salim, Farah
    Ghorbani, Saied
    Javanmard, Davod
    Ghaffari, Hadi
    Monavari, Seyed Hamidreza
    CURRENT HIV RESEARCH, 2021, 19 (01) : 27 - 34
  • [4] HCV genotype determination in monoinfected and HIV co-infected patients in Cuba
    Rodriguez Lay, Licel de los Angeles
    Montalvo Villalba, Maria Caridad
    Bello Corredor, Marite
    Sariego Frometa, Susel
    Marante Hernandez, Jeny
    Duenas Carrera, Santiago
    Sanchez Wong, Meilin
    Samada, Marcia
    Bello Nunez, Milay
    Valdes Alonso, Lidunka
    da Silva Filhoe, Hermes Pedreira
    Huebschen, Judith M.
    Reis, Mitermayer G.
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2012, 106 (12) : 711 - 717
  • [5] Hepatic stearosis is associated with dideoxynucleoside analogues and HCV genotype 3 in HIV/HCV co-infected patients
    McGovern, B
    Ditelberg, J
    Taylor, L
    Gandhi, R
    Christopoulos, K
    Fiore, J
    Graeme-Cook, F
    Schwarzapfel, B
    Chapman, S
    Fiorino, AM
    Rindler, E
    Zaman, T
    Sax, P
    Hibberd, P
    GASTROENTEROLOGY, 2005, 128 (04) : A749 - A749
  • [6] HCV TREATMENT DURATION IN HIV/HCV GENOTYPE 1 CO-INFECTED PATIENTS. RESULTS OF A MULTICENTER RANDOMIZED TRIAL
    Barone, Antonio A.
    Cheinquer, Hugo
    Brandao-Mello, Carlos E.
    Marins, Ed G.
    HEPATOLOGY, 2010, 52 (04) : 361A - 362A
  • [7] Inflammatory cells and apoptosis in HCV and co-infected HCV/HIV patients
    Petrovic, L.
    Rohan, S.
    Hayek, E.
    LIVER INTERNATIONAL, 2006, 26 : 74 - 74
  • [8] Comparison of therapeutic results on HCV and HCV/HIV co-infected patients
    Serra, J. E.
    Guzman, D.
    Velez, J.
    Pinto, P.
    Marques, N. M.
    da Cunha, J. G. Saraiva
    Melico-Silvestre, A.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S144 - S144
  • [9] Prevalence of risk factors for HCV transmission in HIV infected and HIV/HCV co-infected patients
    Bollepalli, S
    Mahthieson, K
    Post, J
    Hillier, A
    Nadir, A
    HEPATOLOGY, 2005, 42 (04) : 423A - 423A
  • [10] EXTENSION OF COMBINATION THERAPY IN HCV/HIV CO-INFECTED GENOTYPE 1 PATIENTS: EFFECT ON SVR
    Hassanein, Tarek
    Pozza, Renee S.
    Biando, Karel
    Richards, Lisa M.
    Petcharaporn, Lita
    Barakat, Fatma
    El Kabany, Mohamed
    HEPATOLOGY, 2009, 50 (04) : 699A - 700A
12345